- Home
- LGHL vs RNAZ Comparison
LGHL vs RNAZ Comparison
Compare LGHL & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGHL
- RNAZ
- Stock Information
- Founded
- LGHL 2015
- RNAZ 2016
- Country
- LGHL Singapore
- RNAZ United States
- Employees
- LGHL N/A
- RNAZ N/A
- Industry
- LGHL Investment Bankers/Brokers/Service
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- LGHL Finance
- RNAZ Health Care
- Exchange
- LGHL Nasdaq
- RNAZ Nasdaq
- Market Cap
- LGHL 4.3M
- RNAZ 4.9M
- IPO Year
- LGHL N/A
- RNAZ 2021
- Fundamental
- Price
- LGHL $0.16
- RNAZ $3.35
- Analyst Decision
- LGHL
- RNAZ Strong Buy
- Analyst Count
- LGHL 0
- RNAZ 1
- Target Price
- LGHL N/A
- RNAZ $20.00
- AVG Volume (30 Days)
- LGHL 5.4M
- RNAZ 143.7K
- Earning Date
- LGHL 01-28-2025
- RNAZ 11-14-2024
- Dividend Yield
- LGHL N/A
- RNAZ N/A
- EPS Growth
- LGHL N/A
- RNAZ N/A
- EPS
- LGHL N/A
- RNAZ N/A
- Revenue
- LGHL $13,659,110.00
- RNAZ N/A
- Revenue This Year
- LGHL N/A
- RNAZ N/A
- Revenue Next Year
- LGHL N/A
- RNAZ N/A
- P/E Ratio
- LGHL N/A
- RNAZ N/A
- Revenue Growth
- LGHL 11.35
- RNAZ N/A
- 52 Week Low
- LGHL $0.13
- RNAZ $2.66
- 52 Week High
- LGHL $1.55
- RNAZ $66.33
- Technical
- Relative Strength Index (RSI)
- LGHL 44.11
- RNAZ 30.32
- Support Level
- LGHL $0.14
- RNAZ $2.90
- Resistance Level
- LGHL $0.17
- RNAZ $3.50
- Average True Range (ATR)
- LGHL 0.03
- RNAZ 0.42
- MACD
- LGHL -0.00
- RNAZ 0.31
- Stochastic Oscillator
- LGHL 10.64
- RNAZ 50.74
About LGHL Lion Group Holding Ltd.
Lion Group Holding Ltd is an investor-focused trading platform that offers various products and services. The company's current business lines include total return swap (TRS) trading business, contracts for difference (CFD) trading services, Hong Kong-based Over-The-Counter (OTC) stock options trading business, and futures and securities brokerage services. It provides these services through its Lion Brokers Pro and a variety of other applications. The company generates a majority of its revenue from its CFD trading services business. Geographically, the firm's key revenue-generating market is Hong Kong.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.